Results 211 to 220 of about 1,404,058 (313)

Neuroinflammation in GAD65 Antibody‐Associated Epilepsy Measured Using [18F]DPA‐714 PET/MRI

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The timing for initiating immunotherapy in patients with glutamic acid decarboxylase 65 (GAD65) antibody‐associated epilepsy is a challenge. We used the translocator protein radioligand [18F]DPA‐714 and PET to evaluate brain microglial activation.
Jingjing Chen, Yuying Zhang, Heyu Zhang, Jinming Zhang, Ningning Wang, Xintong Guo, Yicong Liu, Yue Liu, Xiangsong Zhang, Ziyi Chen, Guanzhong Ni   +10 more
wiley   +1 more source

Tepotinib-Induced Cholangitis in a Patient With Non-Small Cell Lung Cancer: A Case Report. [PDF]

Respirol Case Rep
Hachisu Y, Yoshida K, Hosino Y, Ito K, Uno S, Ezawa K, Arai H, Horie T.   +7 more
europepmc   +1 more source

Trends in Dermatopolymyositis Mortality, 1999–2022: A Nationwide Population‐Based Study, United States

Arthritis Care &Research, EarlyView.
We report the national burden of dermatopolymyositis mortality over the past quarter century using the US national vital statistics data. Age‐standardized mortality rates for dermatopolymyositis decreased at an annual rate of 3.8% each year, which was higher than the annual percent decrease for deaths from all other causes.
Elizabeth Matz, Ram R. Singh
wiley   +1 more source

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review). [PDF]

Oncol Rep
Sharma U, Song J, Kandu H, Zhu Y, Dai Z.
europepmc   +1 more source

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development

Arthritis Care &Research, EarlyView.
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg, Izzy Hartel, Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'Era, Alí Duarte‐García, Victoria P. Werth, Brad Rovin, Reem A. Mustafa, Amy S. Turner, Bené Williams, Brian L. Ung, Hiya Bhavsar, Monique C. Gore‐Massy, Nahirannette Pulido, Natacha Guerrero, Natalie M. Smith, Wambui Machua, Linda T. Hiraki, Mary Beth Son   +20 more
wiley   +1 more source

Statewide Medicaid Expansion and Survival in Resectable Non-Small Cell Lung Cancer.

JAMA Netw Open
Gawdi R, Islam S, Sha C, Liu S, Glassman LR, Hyman KM, Jurado JE, Zeltsman D, Lee PC.   +8 more
europepmc   +1 more source

Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. [PDF]

J Extracell Vesicles
Cáceres-Verschae A, Hååg P, Joelsson S, Hydbring P, Franzén B, Végvári Á, Eide IJZ, Agarwal N, Sahu SS, Stridfeldt F, De Petris L, Dev A, Ekman S, Brustugun OT, Lewensohn R, Viktorsson K.   +15 more
europepmc   +1 more source

O-GlcNAcylation levels predict radiotherapy outcome in non-small cell lung cancer. [PDF]

Transl Lung Cancer Res
Wang X, Ma Y, Dong Y, Wang Y, Yuan J, Yu J, Chen D.   +6 more
europepmc   +1 more source

Immune Checkpoint Inhibitor Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, Accepted Article.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W Cannon, Brian C Sauer, Jorge Rojas, Gregory J Stoddard, Gary A Kunkel, Jessica A. Walsh, Bryant R England, Joshua F Baker, Tawnie J Braaten   +9 more
wiley   +1 more source

Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME

Advanced Functional Materials, EarlyView.
A quinone methide‐gated, self‐immolative, H2O2‐responsive nano‐photosensitizer (Pyz/PS) is developed for targeted immuno‐photodynamic therapy. Pyz/PS selectively activates within tumor microenvironments, restores photosensitizer activity, generates ROS, and depletes intracellular GSH, enhancing oxidative stress.
Jing Li, E Pang, Snehasish Debnath, Jia Hong, Aojun Qiu, Dongeun Kim, Goeun Kim, Minhuan Lan, Min‐Goo Lee, Qian‐Yong Cao, Jong Seung Kim   +10 more
wiley   +1 more source